Trial Profile
A Randomized, Double -Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects and Subjects With Stable Schizophrenia and a Randomized Open-Label, Single Dose, Parallel Design to Evaluate the Relative Bioavailability and Effect of Food on the Pharmacokinetics of TAK-041 Tablet Formulation in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 15 Mar 2022
Price :
$35
*
At a glance
- Drugs TAK 041 (Primary)
- Indications Cognition disorders; Schizophrenia
- Focus Adverse reactions; First in man; Pharmacokinetics
- Sponsors Takeda
- 12 Mar 2022 Results published in the British Journal of Clinical Pharmacology
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 04 Sep 2019 Planned End Date changed from 29 Aug 2019 to 22 Sep 2019.